LATEST NEWS
LATEST ISSUE
Spatialomics delivered to the clinic for improved health outcomes in Barrett’s esophagus
Implementation of Novel Precision Medicine Workflows in the Community Oncology Setting
Scaling Interpretation of Clinical Sequence Data for Rare Diseases
Assessing Measurable Residual Disease as a Genetic Biomarker for Acute Myeloid Leukemia
Validated Oncogenic Drivers: An Important Sourceto Expand Targeted Therapy Access
Data Can Fill Gaps in Antimicrobial Stewardship Left by COVID-19
Imputation and critical variants:Fast becoming essential components for predictive genomics
Moving to Real‑world Applications of Pharmacogenetic Testing
Variability in Somatic Variant Interpretation: Can Software Help?
ARCHIVE ISSUES
September 2022
Articles include:
Why Equitable Access Depends on Comprehensive Genomic Profiling, Clinical Implications and Utility of Polygenic Risk Scores in Women at Elevated Risk for Breast Cancer, Genomic Innovation Democratizes Precision Medicine
Read More
June 2022
Articles include:
The Center for Applied Genomics at The Children’s Hospital of Philadelphia: Perspectives on a Decade with the Electronic Medical Records and Genomics (eMERGE) Consortium, Clinical trials for the management of malignant lymphoma and leukemia.
Read More
March 2022
Articles include:
Applications of Spatial‑Omics in Clinical Translational Cancer Research, Illumina‑SomaLogic Deal to bring together genomics and proteomics technology platforms, How I Learned the Hard Way to Ask Questions About Medications.
Read More
September 2021
Articles include:
The Integration of Personalized Medicine into Healthcare: Advancing the Promise to More Patients, The value of adding RNA sequencing to precision biomarker strategy, As Targeted Therapies Expand Beyond Cancer, Companion Diagnostics Must Improve.
Read More
June 2021
Articles include:
myRabble: A novel patient platform to improve access to personalized medicine, Clinical data and precision medicine: The urgent need for in‑house NGS capabilities at community hospitals.
Read More
